A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A new national analysis provides clinicians with evidence on how chronic obstructive pulmonary disease affects post-discharge outcomes in adults with sickle cell disease hospitalized for acute chest...
A large contemporary U.S. electronic health record analysis highlights elevated risks of severe maternal morbidity and preterm birth among pregnant individuals with sickle cell disease, offering updated...
A new multicenter UK audit evaluated dapagliflozin use in adults with sickle cell disease–associated chronic kidney disease, offering clinicians early insight into safety, tolerability, and renal effects in...
A phase 1b–2 trial published in The New England Journal of Medicine evaluated the combination of two bispecific antibodies, talquetamab and teclistamab, for patients with relapsed or refractory multiple...
New clinical guidance outlines the use of blood-based biomarker tests for Alzheimer’s diagnosis in patients with cognitive impairment, aiming to support more consistent and evidence-based application in...
A phase 3 trial confirms that combining ibrutinib with venetoclax yields superior measurable residual disease clearance, progression-free survival, and overall survival in patients with chronic lymphocytic...
Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
Acalabrutinib demonstrated a significantly safer cardiovascular profile and lower mortality risk compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia based on a large retrospective...
